3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
80
Fluorouracil
74
Oxaliplatin
69
Magnetic Resonance Spectroscopy
61
Leucovorin
58
Gemcitabine
55
Bevacizumab
55
Biopsy
41
Capecitabine
40
Irinotecan
37
Cisplatin
36
Nivolumab
35
pembrolizumab
33
Cetuximab
33
durvalumab
30
Paclitaxel
27
130-nm albumin-bound paclitaxel
27
atezolizumab
20
Folfox protocol
20
Radiotherapy
17
Carboplatin
17
dehydroftorafur
15
Taxes
15
Cyclophosphamide
15
fludarabine
13
X-Rays
13
Radiation
13
trastuzumab deruxtecan
12
Surgical Procedures, Operative
12
Albumin-Bound Paclitaxel
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Gastrointestinal
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled